Modular PMA
PMA submission strategy where a manufacturer submits portions of the PMA (modules) sequentially as they become ready, rather than as a single complete application.
Definition
Modular PMA review permits review of agreed portions of an original PMA as they become available under a shell describing module content and timing. The final module completes the application and initiates the applicable complete-application review process. Earlier scientific review is not deferred until all modules are accepted, and the module structure is not a mandatory three-module sequence. Discuss suitability and the shell with FDA; a formal Pre-Submission meeting is not universally required.What this means in practice
Modular PMA review permits review of agreed portions of an original PMA as they become available under a shell describing module content and timing. The final module completes the application and initiates the applicable complete-application review process. Earlier scientific review is not deferred until all modules are accepted, and the module structure is not a mandatory three-module sequence. Discuss suitability and the shell with FDA; a formal Pre-Submission meeting is not universally required.Examples
- Illustrative: A manufacturer developing an innovative implantable neurostimulator for chronic pain opted for a Modular PMA, submitting preclinical and manufacturing modules while long-term clinical trials were still underway, allowing for early FDA feedback on those components.
- Illustrative: For a novel cardiac assist device requiring extensive human trials, the company engaged in a Modular PMA to get manufacturing quality systems and non-clinical performance data reviewed and accepted by the FDA before the clinical data collection was complete.
- Illustrative: A MedTech firm designing a new generation of artificial pancreas system used the Modular PMA pathway, delivering their device design controls and biocompatibility testing information to the FDA as distinct modules, well in advance of the multi-year pivotal clinical study results.
- •Skipping the pre-submission negotiation of module scope, modules submitted without FDA agreement may be rejected or restarted.
- •Treating modular review as a way to defer hard decisions, FDA may still raise major deficiencies that affect later modules.
- •Plan resources for the agreed number of modules and interactive review cycles rather than assuming exactly three rounds.
Frequently asked questions
Related terms
Grouped by themeEditor's picks
· Hand-selected related conceptsFDA submission mechanisms for changes to PMA-approved devices, selected according to the change and evidence required.
FDA's most stringent device marketing application, required for high-risk Class III devices.
Voluntary mechanism to obtain FDA feedback before a formal premarket submission.
Expedited PMA supplement review pathway where FDA and the manufacturer meet to review minor device or labeling changes in real time.
More in Regulatory
· Same categoryFDA submission demonstrating a device is substantially equivalent to a legally marketed predicate.
Two alternative disclosure mechanisms in a 510(k) submission, a Summary is public on FDA's website; a Statement promises to share Safety & Effectiveness info on request.
Formal mechanism to ask FDA whether a product is a device and, if so, its likely classification.
510(k) variant that relies on FDA guidance, special controls, or recognized consensus standards.
Where this term appears across MedTech Terms.
Sources
4 sourcesSources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.
Official-source claim check:
Modular review begins scientific review before the final module. FDA’s current guidance covers both PMAs and HDEs and was issued January 13, 2025.
Partial review: verified corrections are applied, but this is not a full accuracy certification. The last full review date is unchanged.
Remaining verification limits
- Original merged record reviewed in full. Illustrative examples are hypothetical, not verified case histories. Evidence supports the specific propositions below, not an assertion that every linked page verifies all merged content.
- 1PMA Modular Review GuidanceTier 2 VerifiedFDAfda.gov
- 2European Commission - Medical DevicesTier 2 VerifiedEuropean Commissionhealth.ec.europa.eu
- 3IMDRF DocumentsTier 2 VerifiedIMDRFimdrf.org
- 4FDA January 2025 modular PMA and HDE guidanceTier 2 UncheckedFDAfda.gov
Inline markers like [1] jump to the matching reference above.